Search

Your search keyword '"Park, Yeon Hee"' showing total 1,289 results
Start Over Author "Park, Yeon Hee"
1,289 results on '"Park, Yeon Hee"'

2. Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial

Author

Mukohara, Toru, Park, Yeon Hee, Sommerhalder, David, Yonemori, Kan, Hamilton, Erika, Kim, Sung-Bae, Kim, Jee Hyun, Iwata, Hiroji, Yamashita, Toshinari, Layman, Rachel M., Mita, Monica, Clay, Timothy, Chae, Yee Soo, Oakman, Catherine, Yan, Fengting, Kim, Gun Min, Im, Seock-Ah, Lindeman, Geoffrey J., Rugo, Hope S., Liyanage, Marlon, Saul, Michelle, Le Corre, Christophe, Skoura, Athanasia, Liu, Li, Li, Meng, and LoRusso, Patricia M.

Published
2024
Full Text
View/download PDF

3. Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study

Author

Yamashita, Toshinari, Sohn, Joo Hyuk, Tokunaga, Eriko, Niikura, Naoki, Park, Yeon Hee, Lee, Keun Seok, Chae, Yee Soo, Xu, Binghe, Wang, Xiaojia, Im, Seock-Ah, Li, Wei, Lu, Yen-Shen, Aguilar, Cecilia Orbegoso, Nishijima, Soichiro, Nishiyama, Yuji, Sugihara, Masahiro, Modi, Shanu, and Tsurutani, Junji

Published
2024
Full Text
View/download PDF

5. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Author

Balmaña, Judith, Fasching, Peter A., Couch, Fergus J., Delaloge, Suzette, Labidi-Galy, Intidhar, O’Shaughnessy, Joyce, Park, Yeon Hee, Eisen, Andrea F., You, Benoit, Bourgeois, Hughes, Gonçalves, Anthony, Kemp, Zoe, Swampillai, Angela, Jankowski, Tomasz, Sohn, Joo Hyuk, Poddubskaya, Elena, Mukhametshina, Guzel, Aksoy, Sercan, Timcheva, Constanta V., Park-Simon, Tjoung-Won, Antón-Torres, Antonio, John, Ellie, Baria, Katherine, Gibson, Isabel, and Gelmon, Karen A.

Published
2024
Full Text
View/download PDF

7. Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial

Author

Mukohara, Toru, Park, Yeon Hee, Sommerhalder, David, Yonemori, Kan, Hamilton, Erika, Kim, Sung-Bae, Kim, Jee Hyun, Iwata, Hiroji, Yamashita, Toshinari, Layman, Rachel M., Mita, Monica, Clay, Timothy, Chae, Yee Soo, Oakman, Catherine, Yan, Fengting, Kim, Gun Min, Im, Seock-Ah, Lindeman, Geoffrey J., Rugo, Hope S., Liyanage, Marlon, Saul, Michelle, Le Corre, Christophe, Skoura, Athanasia, Liu, Li, Li, Meng, and LoRusso, Patricia M.

Published
2024
Full Text
View/download PDF

8. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, Park, Yeon Hee, Yamashita, Toshinari, Hurvitz, Sara A, Modi, Shanu, Andre, Fabrice, Krop, Ian E, Farré, Xavier Gonzàlez, You, Benoit, Saura, Cristina, Kim, Sung-Bae, Osborne, Cynthia R, Murthy, Rashmi K, Gianni, Lorenzo, Takano, Toshimi, Liu, Yali, Cathcart, Jillian, Lee, Caleb, and Perrin, Christophe

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Prevention, Clinical Research, Neurosciences, Cancer, Clinical Trials and Supportive Activities, Humans, Female, Breast Neoplasms, Receptor, ErbB-2, Trastuzumab, Immunoconjugates, Camptothecin, Brain Neoplasms, Receptor, erbB-2, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%-77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7-18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation.SignificanceAdvances in treating HER2-positive metastatic breast cancer have greatly improved patient outcomes, but intracranial progression remains an important risk for which few therapeutic options are currently available. T-DXd demonstrated durable efficacy in patients with stable, treated BMs. This article is highlighted in the In This Issue feature, p. 2711.

Published
2022

11. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Author

Park, Yeon Hee, Im, Seock-Ah, Park, Kyunghee, Wen, Ji, Lee, Kyung-Hun, Choi, Yoon-La, Lee, Won-Chul, Min, Ahrum, Bonato, Vinicius, Park, Seri, Ram, Sripad, Lee, Dae-Won, Kim, Ji-Yeon, Lee, Su Kyeong, Lee, Won-Woo, Lee, Jisook, Kim, Miso, Kim, Hyun Seon, Weinrich, Scott L., Ryu, Han Suk, Kim, Tae Yong, Dann, Stephen, Kim, Yu-Jin, Fernandez, Diane R., Koh, Jiwon, Wang, Shuoguo, Park, Song Yi, Deng, Shibing, Powell, Eric, Ravi, Rupesh Kanchi, Bienkowska, Jadwiga, Rejto, Paul A., Park, Woong-Yang, and Kan, Zhengyan

Published
2023
Full Text
View/download PDF

14. Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)

Author

Kim, Jae Sik, Kim, Kyubo, Jung, Wonguen, Shin, Kyung Hwan, Im, Seock-Ah, Kim, Hee-Jun, Kim, Yong Bae, Chang, Jee Suk, Kim, Jee Hyun, Choi, Doo Ho, Park, Yeon Hee, Kim, Dae Yong, Kim, Tae Hyun, Choi, Byung Ock, Lee, Sea-Won, Kim, Suzy, Kwon, Jeanny, Kang, Ki Mun, Chung, Woong-Ki, Kim, Kyung Su, Yoon, Won Sup, Kim, Jin Hee, Cha, Jihye, Oh, Yoon Kyeong, and Kim, In Ah

Published
2023
Full Text
View/download PDF

15. Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

Author

Sung, Changhwan, An, Jinhyeon, Lee, Soohyeon, Park, Jaesoon, Lee, Kang Seon, Kim, Il-Hwan, Han, Ji-Youn, Park, Yeon Hee, Kim, Jee Hyun, Kang, Eun Joo, Hong, Min Hee, Kim, Tae-Yong, Lee, Jae Cheol, Lee, Jae Lyun, Yoon, Shinkyo, Choi, Chang-Min, Lee, Dae Ho, Yoo, Changhoon, Kim, Sang-We, Jeong, Jae Ho, Seo, Seyoung, Kim, Sun Young, Kong, Sun-Young, Choi, Jung Kyoon, and Park, Sook Ryun

Published
2023
Full Text
View/download PDF

16. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

Author

Fehm, Tanja, Cottone, Francesco, Dunton, Kyle, André, Fabrice, Krop, Ian, Park, Yeon Hee, De Laurentiis, Michelino, Miyoshi, Yasuo, Armstrong, Anne, Borrego, Manuel Ruiz, Yerushalmi, Rinat, Duhoux, Francois P, Takano, Toshimi, Lu, Wenjing, Egorov, Anton, and Kim, Sung-Bae

Published
2024
Full Text
View/download PDF

18. Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial

Author

Lee, Dae-Won, Jung, Kyung Hae, Lee, Kyung-Hun, Park, Yeon Hee, Lee, Keun Seok, Sohn, Joohyuk, Ahn, Hee Kyung, Jeong, Jae Ho, Koh, Su-Jin, Kim, Jee Hyun, Kim, Han Jo, Lee, Kyoung Eun, Kim, Hee-Jun, Yang, Yae-Won, Park, Kyong Hwa, Lee, Jieun, Won, Hye Sung, Kim, Tae-Yong, and Im, Seock-Ah

Published
2024
Full Text
View/download PDF

21. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

Author

Ciruelos, Eva Maria, Rugo, Hope S, Mayer, Ingrid A, Levy, Christelle, Forget, Frédéric, Mingorance, Juan Ignacio Delgado, Safra, Tamar, Masuda, Norikazu, Park, Yeon Hee, Juric, Dejan, Conte, Pierfranco, Campone, Mario, Loibl, Sibylle, Iwata, Hiroji, Zhou, Xiaolei, Park, Jinhee, Ridolfi, Antonia, Lorenzo, Ines, and André, Fabrice

Subjects
Clinical Research, Breast Cancer, Cancer, Clinical Trials and Supportive Activities, Pain Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Clinical Trials, Phase III as Topic, Cohort Studies, Double-Blind Method, Female, Fulvestrant, Humans, Mutation, Progression-Free Survival, Quality of Life, Randomized Controlled Trials as Topic, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeIn the phase III SOLAR-1 trial (NCT02437318), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. We assessed health-related quality of life using patient-reported outcome measures in these patients.Materials and methodsIn the PIK3CA-mutant cohort, 341 patients were randomly assigned 1:1 to receive alpelisib 300 mg daily or placebo plus fulvestrant 500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles. Patient-reported outcomes were evaluated with the European Organisation for Research and Treatment of Cancer QoL of Cancer Patients and Brief Pain Inventory-Short Form questionnaires. Changes from baseline and time to 10% deterioration were analyzed using repeated measurement models and Cox models, respectively.ResultsGlobal Health Status/QoL and functional status were maintained from baseline (mean changes < 10 points) in the alpelisib (overall change from baseline [95% CI], -3.50 [-8.02 to 1.02]) and placebo arms (overall change from baseline [95% CI], 0.27 [-4.48 to 5.02]). Overall treatment effect in Global Health Status/QoL was not significantly different between arms (-3.77; 95% CI, -8.35 to 0.80; P = .101). Time to 10% deterioration for Global Health Status/QoL was similar between arms (hazard ratio, 1.03; 95% CI, 0.72 to 1.48). Compared with placebo, deterioration in social functioning and in diarrhea, appetite loss, nausea or vomiting, and fatigue symptom subscales occurred with alpelisib. Numerical improvement in Worst Pain was observed with alpelisib versus placebo (42% v 32%, week 24; P = .090).ConclusionIn SOLAR-1, there was no statistical difference in deterioration of Global Health Status/QoL between arms, whereas symptom subscales favored placebo for diarrhea, appetite loss, nausea or vomiting, and fatigue, known side effects of alpelisib. Treatment decisions must consider efficacy and tolerability; taken with clinical efficacy, these results support the benefit-risk profile of alpelisib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative PIK3CA-mutated advanced breast cancer.

Published
2021

23. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Author

Kuemmel, Sherko, Harper-Wynne, Catherine, Park, Yeon Hee, Franke, Fábio, de Laurentiis, Michelino, Schumacher-Wulf, Eva, Eiger, Daniel, Heeson, Sarah, Cardona, Andrés, Özyilkan, Özgür, Morales-Vàsquez, Flavia, Metcalfe, Ciara, Hafner, Marc, Restuccia, Eleonora, and O’Shaughnessy, Joyce

Published
2024
Full Text
View/download PDF

25. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Author

Hurvitz, Sara A, Bardia, Aditya, Quiroga, Vanesa, Park, Yeon Hee, Blancas, Isabel, Alonso-Romero, José Luis, Vasiliev, Aleksandr, Adamchuk, Hryhoriy, Salgado, Marcelo, Yardley, Denise A, Berzoy, Oleksandr, Zamora-Auñón, Pilar, Chan, David, Spera, Gonzalo, Xue, Cloris, Ferreira, Erika, Badovinac Crnjevic, Tanja, Pérez-Moreno, Pablo Diego, López-Valverde, Vanesa, Steinseifer, Jutta, Fernando, Tharu M, Moore, Heather M, and Fasching, Peter A

Published
2023
Full Text
View/download PDF

26. Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.

Author

Park, Yeon Hee, primary, Lee, Kyung-Hun, additional, Kim, Gun Min, additional, Kang, Seok Yun, additional, Lee, Keun Seok, additional, Kim, Jee Hyun, additional, Lee, Kyoung Eun, additional, Ahn, Hee Kyung, additional, Lee, Moon Hee, additional, Kim, Hee Jun, additional, Kim, Hanjo, additional, Koh, Su-Jin, additional, Kim, Ji-Yeon, additional, Sohn, Joohyuk, additional, Kim, Sung-Bae, additional, Ahn, Jin Seok, additional, Kim, Seonwoo, additional, Cho, Hyun, additional, Jung, Kyung Hae, additional, and Im, Seock-Ah, additional

Published
2024
Full Text
View/download PDF

28. Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).

Author

Lee, Jieun, primary, Lee, Dae-Won, additional, Im, Seock-Ah, additional, Kim, Min Hwan, additional, Kim, Jee Hung, additional, Park, Kyong Hwa, additional, Byun, Jae Ho, additional, Lee, Kyoung Eun, additional, Kang, Myoung Joo, additional, Koh, Su-Jin, additional, Hong, Soojung, additional, Won, Hye Sung, additional, Kim, Han Jo, additional, Park, In Hae, additional, Shin, Seong Hoon, additional, Baek, Sun Kyung, additional, Kim, Seul-Gi, additional, Koh, Sung Ae, additional, Jung, Joo Young, additional, and Park, Yeon Hee, additional

Published
2024
Full Text
View/download PDF

30. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Author

Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, and Krop, Ian

Subjects
Cancer, Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Consolidation Chemotherapy, Female, Humans, Immunoconjugates, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung Diseases, Interstitial, Middle Aged, Progression-Free Survival, Receptor, ErbB-2, Trastuzumab, DESTINY-Breast01 Investigators, Receptor, erbB-2, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.MethodsIn this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.ResultsOverall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).ConclusionsTrastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).

Published
2020

32. Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study

Author

Tan, Ryan Ying Cong, primary, Ong, Whee Sze, additional, Lee, Kyung-Hun, additional, Park, Seri, additional, Iqbal, Jabed, additional, Park, Yeon Hee, additional, Lee, Jeong Eon, additional, Yu, Jong Han, additional, Lin, Ching-Hung, additional, Lu, Yen-Shen, additional, Ono, Makiko, additional, Ueno, Takayuki, additional, Naito, Yoichi, additional, Onishi, Tatsuya, additional, Lim, Geok-Hoon, additional, Tan, Su-Ming, additional, Lee, Han-Byoel, additional, Koh, Jiwon, additional, Han, Wonshik, additional, Im, Seock-Ah, additional, Tan, Veronique Kiak Mien, additional, Phyu, Nitar, additional, Wong, Fuh-Yong, additional, Tan, Puay Hoon, additional, and Yap, Yoon-Sim, additional

Published
2024
Full Text
View/download PDF

33. A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer

Author

Kim, Chang Min, primary, Park, Kyong Hwa, additional, Yu, Yun Suk, additional, Kim, Ju Won, additional, Park, Jin Young, additional, Park, Kyunghee, additional, Yu, Jong-Han, additional, Lee, Jeong Eon, additional, Sim, Sung Hoon, additional, Seo, Bo Kyoung, additional, Kim, Jin Kyeoung, additional, Lee, Eun Sook, additional, Park, Yeon Hee, additional, and Kong, Sun-Young, additional

Published
2024
Full Text
View/download PDF

34. Age and ethnic-driven molecular and clinical disparity of East Asian breast cancers

Author

Lee, Ji Yoon, primary, Chung, Min Sung, additional, Choi, Jong Gwon, additional, Sim, Sung Hoon, additional, Kim, Hyo Jeong, additional, Kim, Jeong Eun, additional, Lee, Kyoung Eun, additional, Park, Yeon Hee, additional, Kang, Myoung Joo, additional, Ahn, Mi Sun, additional, Chae, Yee Soo, additional, Park, Ji Hyun, additional, Kim, Jee Hyun, additional, Kim, Gun Min, additional, Byun, Jae Ho, additional, Park, Keon Uk, additional, Kim, Ju Won, additional, Jung, Seung Pil, additional, Lee, Jung Hyun, additional, An, Jung Seok, additional, Jang, Byunghyun, additional, Yoon, Dayoung, additional, Kim, Jiwon, additional, Hong, Jisoo, additional, Koo, Harim, additional, Cho, Kyu Ran, additional, Kim, Cheol Yong, additional, Sa, Jason K., additional, Park, Kyong Hwa, additional, and Lee, Ji Won, additional

Published
2024
Full Text
View/download PDF

38. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis

Author

Tan, Ryan Shea Ying Cong, Ong, Whee Sze, Lee, Kyung-Hun, Lim, Abner Herbert, Park, Seri, Park, Yeon Hee, Lin, Ching-Hung, Lu, Yen-Shen, Ono, Makiko, Ueno, Takayuki, Naito, Yoichi, Onishi, Tatsuya, Lim, Geok-Hoon, Tan, Su-Ming, Lee, Han-Byoel, Ryu, Han Suk, Han, Wonshik, Tan, Veronique Kiak Mien, Wong, Fuh-Yong, Im, Seock-Ah, Tan, Puay Hoon, Chan, Jason Yongsheng, and Yap, Yoon-Sim

Published
2022
Full Text
View/download PDF

44. Digital workflow for creating a coolant channel for direct irrigation through an implant surgical guide.

Author

Park, Yeon-Hee, Oh, Won-suk, and Lee, Jung-Jin

Abstract

Heat elicited during the osteotomy for implant placement may have a significant impact on the vitality of surrounding bone and on the healing capacity for osseointegration. This article describes a digital workflow for creating a coolant channel for the direct irrigation of the osteotomy site through an implant surgical guide. This technique can be particularly advantageous when the surgical guide restricts access for direct irrigation of the osteotomy site. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results